Ad
related to: dexcom stock analysis
Search results
Results From The WOW.Com Content Network
On Thursday, Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4%, while ...
DXCM data by YCharts. But despite the company's volatile streak and expensive-looking valuation, DexCom's dominance in the CGM market and strong financial results have led to excellent performances.
Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a ...
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels. The company slashed its forecast last year, blaming a ...
Before you buy stock in DexCom, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and DexCom wasn’t ...
At about $69 per share, DexCom's stock isn't that far off its 52-week low of $62.34 and is miles away from its 52-week high of $142. However, there remain good reasons to invest in the company.
Right now, DexCom's stock is valued at a price-to-earnings (P/E) multiple of 42. Assuming that valuation holds up over time, it'd have a market cap of roughly $469 billion in 2034, or 1,605% ...
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth.